European biotech companies, as well as those from Australia and New Zealand, are being drawn to the U.S. because it has the largest investment resources and a large profitable market for their drugs. Most of the companies set up small offices in the U.S. to tap its financial resources while leaving their scientists back in the home country.

Full Story:

Related Summaries